Sumitomo Mitsui Trust Group Inc. Sells 39,987 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Sumitomo Mitsui Trust Group trimmed its position in Edwards Lifesciences by 2.9%, selling 39,987 shares and ending the quarter with 1,341,925 shares worth about $114.4 million (≈0.23% ownership).
• Q4 results showed EPS of $0.58 (missing estimates by $0.04) while revenue rose to $1.57 billion (beating expectations); management set Q1 2026 EPS guidance of $0.70–$0.76 and analysts forecast ~2.45 EPS for the fiscal year with a consensus target of $95.74.
• Insiders sold 86,058 shares last quarter (including the VP and CFO), insider ownership is about 0.31%, institutional investors hold 79.46%, and the stock trades near $78 with a market cap of roughly $45 billion and a P/E of ~42.6.

Sumitomo Mitsui Trust Group Inc. lessened its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 2.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,341,925 shares of the medical research company's stock after selling 39,987 shares during the period. Sumitomo Mitsui Trust Group Inc. owned approximately 0.23% of Edwards Lifesciences worth $114,399,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Level Four Advisory Services LLC grew its position in Edwards Lifesciences by 3.7% in the 3rd quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company's stock worth $257,000 after purchasing an additional 119 shares during the period. Colonial Trust Co SC boosted its stake in shares of Edwards Lifesciences by 0.4% during the 3rd quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company's stock worth $2,504,000 after acquiring an additional 120 shares during the last quarter. Evermay Wealth Management LLC boosted its stake in shares of Edwards Lifesciences by 4.0% during the 4th quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company's stock worth $282,000 after acquiring an additional 128 shares during the last quarter. Howard Capital Management Inc. boosted its stake in shares of Edwards Lifesciences by 3.3% during the 3rd quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company's stock worth $322,000 after acquiring an additional 132 shares during the last quarter. Finally, Florida Trust Wealth Management Co boosted its stake in shares of Edwards Lifesciences by 1.5% during the 4th quarter. Florida Trust Wealth Management Co now owns 8,810 shares of the medical research company's stock worth $751,000 after acquiring an additional 132 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Up 0.2%

EW opened at $78.02 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. Edwards Lifesciences Corporation has a fifty-two week low of $68.63 and a fifty-two week high of $87.89. The firm's fifty day moving average is $81.32 and its 200 day moving average is $82.06. The stock has a market cap of $44.98 billion, a price-to-earnings ratio of 42.63, a price-to-earnings-growth ratio of 2.03 and a beta of 0.95.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts' consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm had revenue of $1.57 billion for the quarter, compared to analysts' expectations of $1.54 billion. During the same quarter last year, the firm posted $0.59 EPS. The firm's quarterly revenue was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 24,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the transaction, the vice president owned 21,266 shares in the company, valued at approximately $1,782,941.44. The trade was a 53.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the transaction, the chief financial officer owned 39,699 shares in the company, valued at approximately $3,177,507.96. This trade represents a 24.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 86,058 shares of company stock worth $7,118,636. 0.31% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have recently weighed in on EW shares. Weiss Ratings reiterated a "hold (c)" rating on shares of Edwards Lifesciences in a research note on Wednesday, January 21st. Truist Financial set a $89.00 price target on shares of Edwards Lifesciences and gave the stock a "hold" rating in a research note on Wednesday, February 11th. Piper Sandler reiterated an "overweight" rating and set a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Barclays reiterated an "overweight" rating and set a $104.00 price target (up from $103.00) on shares of Edwards Lifesciences in a research note on Monday, January 12th. Finally, Wells Fargo & Company lifted their price target on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 11th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences has an average rating of "Moderate Buy" and a consensus target price of $95.74.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.